Liquid Biopsy ctDNA Adaptive Therapy — PatSnap Eureka
ctDNA-Guided Adaptive Therapy: Liquid Biopsy for Real-Time Resistance Monitoring
Circulating tumor DNA (ctDNA) liquid biopsy has emerged as a transformative, minimally invasive platform for real-time tumor genomic profiling—enabling dynamic treatment switching, early resistance detection, and molecular response monitoring across NSCLC, melanoma, breast cancer, and beyond.
ctDNA Liquid Biopsy Across 10+ Solid Tumor Indications
Liquid biopsy research spans lung cancer (NSCLC predominates), metastatic melanoma, colorectal carcinoma, breast cancer, prostate cancer, hepatocellular carcinoma, ovarian cancer, urothelial carcinoma, B-cell lymphoma, and primary CNS lymphoma (PCNSL). Across these indications, ctDNA—comprising tumor-derived fragments of cell-free DNA (cfDNA) carrying somatic mutations—is positioned as the primary molecular target for non-invasive tumor interrogation.
EGFR mutations (sensitizing and resistance variants, including T790M exon 20) are central to NSCLC targeted therapy guidance and resistance monitoring, with FDA-cleared companion diagnostics. KRAS, NRAS, and BRAF are key oncogenic drivers surveilled in colorectal cancer, melanoma, and NSCLC, with digital PCR-based quantification used to track anti-PD1 kinetics. TP53 is identified as the most commonly mutated gene across NSCLC ctDNA NGS panels, used as a tracking mutation for longitudinal monitoring in patients without targetable drivers.
Regulatory acceptance of ctDNA companion diagnostics is advancing rapidly. FDA-cleared companion diagnostics for EGFR mutation testing are explicitly noted in retrieved results, while NGS-based plasma profiling is entering routine oncology practice. PatSnap's life sciences intelligence platform tracks the full innovation landscape across these molecular targets and indications.
Blood TMB (bTMB) and tumor mutational burden (TMB) are identified as ctDNA-derivable biomarkers for immune checkpoint inhibitor (ICI) response prediction across NSCLC and melanoma. PIK3CA methylation and mutation are demonstrated in a dual-biomarker electrochemical detection platform using PNA-AuNP biosensors. Chromatin remodeling genes (KMT2C, BCOR, KDM5C) mutations are associated with ICI response in NSCLC, with potential for ctDNA-based monitoring.
Seven ctDNA-Driven Adaptive Therapy Approaches
From EGFR TKI switching to mathematical model-guided drug holidays, retrieved results document a spectrum of ctDNA-enabled adaptive therapy strategies across solid tumor types.
ctDNA-Guided Targeted Therapy Selection and Switching
Serial blood sampling followed by digital PCR or NGS-based mutation detection provides real-time tumor genotyping to identify when resistance mutations emerge, triggering treatment switch decisions without mandatory re-biopsy. In NSCLC, ctDNA-based EGFR testing (cobas® EGFR v2, Crystal Digital PCR, NGS panels) detects sensitizing mutations and resistance mutations (notably T790M) longitudinally across four prospective time points, with specific utility in identifying acquired resistance necessitating osimertinib escalation.
FDA-approved CDx for EGFR; ALK/BRAF panel testing in clinical practicectDNA Kinetics as Early ICI Response Predictors
Serial on-treatment ctDNA measurements at weeks 2–4 post-initiation serve as predictive biomarkers for response or primary resistance to immune checkpoint inhibitors. In metastatic BRAF/NRAS-mutated melanoma treated with anti-PD1, biological progression (significant ctDNA increase) at week 2 or 4 was associated with 4-month PFS of 0% and 1-year OS of 13% (n=12/102). In NSCLC, early ctDNA changes by NGS (eTAm-Seq) predicted response to first-line pembrolizumab ± chemotherapy prior to first radiological assessment.
Translational/clinical validation — not yet approved CDx indicationNGS-Based Comprehensive Genomic Profiling of Plasma ctDNA
Platforms including CAPP-Seq, TAm-Seq/eTAm-Seq, WES, WGS, and targeted amplicon panels enable simultaneous identification of driver mutations, resistance mutations, copy number variants (CNVs), and TMB from a single blood draw. At City of Hope, 1,688 somatic mutations were detected across 473 ctDNA samples from 370 NSCLC patients; 177 samples had at least one actionable mutation with FDA-approved matched therapies. A machine learning-guided WGS platform (MRD-EDGE) improves SNV signal enrichment by 300-fold compared to prior noise suppression approaches.
Guardant Health NGS in clinical use; WGS/MRD platforms in validationDigital PCR–Based Quantitative ctDNA Monitoring
Droplet digital PCR (ddPCR) and Crystal Digital PCR are precision quantification platforms for tracking known mutations longitudinally with high sensitivity. A workflow combining targeted NGS (baseline mutation identification) followed by ddPCR (serial monitoring) was evaluated in 40 NSCLC patients; mutations were detected in 21 patients, predominantly TP53, enabling treatment monitoring in patients without targetable mutations. In uveal melanoma, ddPCR-based early during-treatment ctDNA assessment accurately predicted clinical benefit to PKCi-based therapy via ROC curve analysis.
Widely used in research and clinical trial monitoringPersonalized / Individualized ctDNA Panels
Tumor-specific, patient-customized ctDNA panels built from whole-exome sequencing of baseline tumor tissue target high-clonal-fraction patient-specific somatic mutations rather than universal cancer hotspots. Individualized ctDNA fingerprints were developed in 521 Chinese patients across 12 cancer types and 7 treatments; customized panels had a median of 19 somatic mutations, with 66.8% of patients ctDNA-positive. Individually customized panels (ICPs) tracked 80–100% of dominant predicted neoantigens during ICI treatment in NSCLC.
Median 19 somatic mutations per panel; 66.8% ctDNA positivityMulti-Analyte Liquid Biopsy (ctDNA + CTCs + Exosomes)
Comprehensive "encyclopedic liquid biopsy" (eLB) platforms integrate ctDNA mutation profiling, exosomal mRNA differential expression, and CTC phenotyping for therapeutic guidance. The LIQUID IMPACT trial (phase II/III, CTRI/2019/02/017548) enrolled patients with solid tumors where standard of care had failed and tissue biopsy was contraindicated. In metastatic breast cancer, ERBB2/ERBB3 overexpression in CTCs correlated with disease progression with 87% specificity across 27 patients in longitudinal multi-parametric analysis.
87% specificity — ERBB2/ERBB3 CTC overexpression for progressionKey Clinical Data Points from ctDNA Liquid Biopsy Research
Quantitative findings from retrieved patent and literature records, visualised from study-reported values.
ALK ctDNA Status and Progression-Free Survival in NSCLC
Detectable ctDNA prior to ALK inhibitor therapy predicted significantly worse median PFS (8.7 vs. 15.2 months, p=0.028) — Aarhus University Hospital, 2020.
Biological ctDNA Progression Outcomes in Anti-PD1 Melanoma
Biological progression (ctDNA rise) at week 2–4 in BRAF/NRAS-mutated melanoma: 4-month PFS 0%, 1-year OS 13% (n=12/102). CHU Nantes, 2021.
ctDNA Profiling Technology Landscape by Development Stage
Positioning of major ctDNA analytical platforms from clinical use to translational validation, based on retrieved evidence signals.
Individualized ctDNA Panels: Scale and Positivity (521 Patients)
GenomiCare Biotechnology study: 521 patients, 12 cancer types, 7 treatments. Median panel size 19 mutations; 66.8% ctDNA-positive at baseline.
Critical ctDNA Biomarker Findings by Target
Quantitative evidence from retrieved clinical studies, organised by actionable molecular target and clinical significance.
EGFR — Most Extensively Covered Target
ctDNA-based detection of sensitizing EGFR mutations (exon 19 deletions, L858R) guides TKI initiation; emergence of T790M in plasma ctDNA signals acquired resistance and need for third-generation TKI switch. In 641 plasma samples from 57 oncogene-addicted NSCLC patients followed prospectively, ctDNA mutation detection at diagnosis reached 77% (10/13 cases); molecular alterations at progression were detected in ctDNA before radiological confirmation in multiple cases. Multi-parametric liquid biopsy combining EGFR ctDNA with CTC counts and neutrophil-to-lymphocyte ratio (NLR) further stratifies TKI-treated NSCLC patients.
BRAF/NRAS — Melanoma Longitudinal Monitoring
Plasma BRAF V600E and NRAS variants quantified by ddPCR at baseline and serially during targeted therapy (vemurafenib, dabrafenib, trametinib) and immunotherapy (ipilimumab, nivolumab, pembrolizumab) in 48 advanced melanoma patients; ctDNA detected in 73% (35/48) at baseline; lower baseline ctDNA associated with longer PFS under both modalities. Decreasing ctDNA within 12 weeks of systemic therapy was strongly concordant with treatment response (Cohen's κ=0.798) and predictive of longer PFS.
From Single-Gene PCR to Machine Learning-Guided WGS
The evolution of ctDNA analytical platforms spans from targeted hotspot assays to comprehensive whole-genome approaches. Guardant Health's validated commercial NGS assay identified genomic alterations in 83% of NSCLC subjects, with TP53, KRAS, and EGFR as most commonly mutated genes in retrieved results.
Whole-genome ctDNA approaches (WGS and WGS bisulfite sequencing) were applied prospectively in 91 advanced solid tumor patients to define "molecular progression" (MP) and "major molecular response" (MMR) earlier than imaging-based RECIST criteria. This represents a paradigm shift: ctDNA-defined molecular endpoints preceding radiological confirmation by weeks to months.
The machine learning-guided WGS platform MRD-EDGE further improves signal enrichment for SNVs by 300-fold compared to prior noise suppression approaches, enabling minimal residual disease (MRD) detection at very low tumor fractions. This positions liquid biopsy for ultra-early relapse detection and adaptive therapy triggers.
A dual-biomarker electrochemical detection platform using PNA-AuNP biosensors simultaneously quantifies PIK3CA methylation and mutation—demonstrating the innovation frontier beyond sequencing-based approaches. PatSnap's life sciences platform tracks patent filings across all these technology clusters in real time.
For comprehensive coverage of how leading oncology R&D teams are using liquid biopsy intelligence to prioritise pipeline assets, PatSnap Eureka provides patent, literature, and clinical trial data in a single searchable interface.
Liquid Biopsy ctDNA Adaptive Therapy — key questions answered
ctDNA comprises tumor-derived fragments of cell-free DNA (cfDNA) carrying somatic mutations, and is positioned as the primary molecular target for non-invasive tumor interrogation. Liquid biopsy—particularly the analysis of circulating tumor DNA (ctDNA)—has emerged as a transformative, minimally invasive platform for real-time tumor genomic profiling, enabling dynamic treatment adaptation, early resistance detection, and molecular response monitoring across multiple solid tumor types.
Retrieved results span lung cancer (non-small cell lung cancer, NSCLC, predominates), metastatic melanoma, colorectal carcinoma, breast cancer, prostate cancer, hepatocellular carcinoma, ovarian cancer, urothelial carcinoma, B-cell lymphoma, and primary central nervous system lymphoma (PCNSL).
ctDNA levels rapidly decline upon effective tumor cell killing by ICI, whereas rising or stable ctDNA ("biological progression") at early on-treatment timepoints signals immunotherapy futility, providing an opportunity to switch therapy before radiological progression is evident. In metastatic BRAF/NRAS-mutated melanoma treated with anti-PD1, biological progression at week 2 or 4 was associated with 4-month PFS of 0% and 1-year OS of 13% (n=12/102), validated across derivation and validation cohorts totaling 102 patients.
NGS-based ctDNA platforms—including CAPP-Seq, TAm-Seq/eTAm-Seq, whole-exome sequencing (WES), whole-genome sequencing (WGS), and targeted amplicon panels—enable simultaneous identification of driver mutations, resistance mutations, copy number variants (CNVs), and TMB from a single blood draw. At City of Hope, 1,688 somatic mutations were detected across 473 ctDNA samples from 370 NSCLC patients; 177 samples had at least one actionable mutation with FDA-approved matched therapies.
Detectable ctDNA prior to ALK inhibitor therapy was associated with worse progression-free survival (median 8.7 vs. 15.2 months, p=0.028); ctDNA positivity within two months of ALK inhibitor therapy onset was associated with early resistance.
Tumor-specific, patient-customized ctDNA panels are built from whole-exome sequencing (WES) of baseline tumor tissue—targeting high-clonal-fraction patient-specific somatic mutations rather than universal cancer hotspots—for longitudinal monitoring. Individualized ctDNA fingerprints were developed in 521 Chinese patients across 12 cancer types and 7 treatments; customized panels had a median of 19 somatic mutations, with 66.8% of patients ctDNA-positive, enabling therapy response and recurrence monitoring.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka Your ctDNA QuestionsMap the Full ctDNA Liquid Biopsy Innovation Landscape in Minutes
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — search patents, literature, and clinical signals across EGFR, ALK, BRAF, and beyond.
References
- Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in NSCLC — PatSnap Eureka Literature
- Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC — University of Campania Luigi Vanvitelli, 2020
- Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy — PatSnap Eureka Literature
- Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive NSCLC — Aarhus University Hospital, 2020
- A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations — Aarhus University Hospital, 2018
- Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer — Guardant Health, 2016
- Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study — CHU Nantes, 2021
- Early plasma ctDNA changes to predict response to first-line pembrolizumab +/- chemotherapy in NSCLC — Dana-Farber Cancer Institute, 2020
- Circulating tumor DNA evaluated by NGS is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced NSCLC
- Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in NSCLC — City of Hope
- Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors
- Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoring — MRD-EDGE, 2022
- Individualized ctDNA Fingerprints to Monitor Treatment Response and Recurrence in Multiple Cancer Types — GenomiCare Biotechnology, 2019
- Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma — Edith Cowan University, 2015
- Multi-Analyte Liquid Biopsies for Treatment Guidance in Advanced Refractory Cancers: LIQUID IMPACT Trial — Broomsfield Hospital, 2020
- Longitudinal Multi-Parametric Liquid Biopsy in Metastatic Breast Cancer — University Hospital Essen, 2021
- Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models — H. Lee Moffitt Cancer Center, 2021
- National Center for Biotechnology Information (NCBI) — cfDNA and ctDNA research repository
- U.S. Food and Drug Administration — Companion Diagnostic Approvals
- EORTC — RECIST criteria and oncology endpoints
- National Human Genome Research Institute — Next-Generation Sequencing
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.